Charles Andrews
Pulmonary Disease · San Antonio, TXNPI 1467459578
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Boehringer Ingelheim at 25.8% of the total. Reporting peaked in 2019 at $5,920 and has fallen 99.7% since, to $20 in 2025.
Across 47 payments — averaging $237.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- Glenmark Therapeutics Inc.$2K
- Modernatx, Inc.$2K
- Bayer Healthcare LLC$1K
- Pfizer$1K
- Boehringer Ingelheim International GmbH$1K
- plus $1K from 5 others
Across 2,378 payments — averaging $7136.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$7.1M
- GSK$3M
- Merck$2.6M
- Modernatx, Inc.$1.9M
- Boehringer Ingelheim$931K
- Biontech SE$477K
- plus $983K from 13 others
What the payments were for
- Consulting fees$5,13546%
- Travel & lodging$3,58432%
- Food & beverage$2,37321%
- Education$571%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 7 | $2,883 |
| Glenmark Therapeutics Inc. | 1 | $1,683 |
| Modernatx, Inc. | 4 | $1,570 |
| Bayer Healthcare LLC | 1 | $1,439 |
| Pfizer | 6 | $1,332 |
| Boehringer Ingelheim International GmbH | 11 | $1,156 |
| Merck | 10 | $617 |
| GSK | 3 | $200 |
| Mylan Specialty L.p. | 1 | $125 |
| Alk-abello, Inc | 1 | $117 |
| AbbVie(2 entities) | 2 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mupirocin Cream$1,683
- Vitrakvi$1,439
- OFEV$404
- V114$247
- Yupelri$125
- TRELEGY ELLIPTA$123
- Odactra$117
- Ragwitek$117
- Grastek$117
How this compares
$11,168 in reported general payments places this provider in the 80th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in San Antonio
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- David MarksSan Antonio$453K
- Rodolfo Estrada AnzuetoSan Antonio$300K
- Ali AbediSan Antonio$269K
- Napoleon Puente CuellarSan Antonio$208K
- Soma JyothulaSan Antonio$129K
- Anoop NambiarSan Antonio$119K
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.